Amniotic epithelial cell culture medium and culture method
Through the culture medium and methods of specific formulas, the problem of limited number of amniotic epithelial cells is solved, stable passage and large-scale culture of cells is achieved, clinical needs are met, production costs are reduced, and quality control operability is improved.
Patent Information
- Application Number
- CN202411283443.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to cultivate human amniotic epithelial cells (hAECs) on a large scale, and their isolation efficiency is low and their pluripotency is easily lost during passage, which limits their application in regenerative therapy.
A solution containing Rho kinase inhibitor, p38MAPK inhibitor, protein kinase C inhibitor, L-glutamine, MEM non-essential amino acid, sodium pyruvate, epidermal growth factor, β-mercaptoethanol, basic fibroblast growth The culture medium of factor, hydrocortisone and insulin combined with specific cell isolation and culture methods improves the number of passages and stability of cells.
It significantly improves the number of passages, stability and cell growth of amniotic epithelial cells, reduces production costs, improves the operability of quality control, and meets clinical needs.
Smart Images

Figure CN119020268A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and more particularly to an amniotic epithelial cell culture medium and a culture method. Background Art
[0002] The placenta is an immune barrier between the fetus and the mother's immune system. The amnion is an epithelial cell-lined cavity within the placenta that contains amniotic fluid. The amnion is a thin, avascular tissue of fetal origin composed of cuboidal and columnar epithelial cells that are interconnected by numerous desmosomes, in contact with the amniotic fluid on the fetal side, and attached to a thick basal lamina on the maternal side.
[0003] Human amniotic epithelial cells (hAECs) and amniotic mesenchymal stem cells (hAMSCs) can be isolated from the epithelial cell layer and the underlying avascular mesenchymal matrix of the basement membrane of the amnion, respectively. The marker expression profiles of hAECs and hAMSCs are significantly different. hAECs are flat, cubic, and columnar cells formed by the multipotent placental ectoderm on day 8 after fertilization. hAECs are able to differentiate into cells of all three germ layers and are non-tumorigenic and non-immunogenic. In addition, hAECs lack the expression of major HLA molecules due to their embryonic origin and can be implanted into immune-competent hosts without being rejected by the host immune system. Unlike iPSCs, hAECs do not form tumors or teratomas, have immunomodulatory and anti-inflammatory properties, and have significant advantages over other stem cell sources. However, due to the low efficiency of hAECs isolation, the number of passages after in vitro expansion is limited, and during the culture process, the pluripotency of hAECs is easily reduced, and they are transdifferentiated into mesenchymal stem cells, which greatly limits their application. To date, published protocols for culturing hAECs have been unable to scale up hAECs without significantly compromising their unique and privileged properties, hampering their widespread application in regenerative therapies.
[0004] Therefore, providing a method for batch culturing hAECs cells is an urgent problem to be solved by those skilled in the art. Summary of the invention
[0005] In view of this, the present invention provides an amniotic epithelial cell culture medium and a culture method.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] A culture medium for amniotic epithelial cells, comprising: DMEM / F-12 containing 10 μM of a Rho kinase inhibitor, 10 μM of a p38 MAPK inhibitor, 10 μM of a protein kinase C inhibitor, 2 mM of L-glutamine, 1% of a MEM non-essential amino acid solution (100×), 1% of a MEM amino acid solution (50×), 1 mM of sodium pyruvate, 20 ng / mL of an epidermal growth factor (EGF), 55 μM of β-mercaptoethanol, 50 ng / mL of a basic fibroblast growth factor, 0.4 μg / ml of hydrocortisone, 5 μg / ml of insulin, and 5% of UltraGRO.
[0008] Another object of the present invention is to provide a method for culturing amniotic epithelial cells, wherein the amniotic epithelial cells are cultured using the above culture medium at a temperature of 37° C. and 5% CO 2 .
[0009] Preferably, when the cell confluence is greater than 80%, 300 IU / ml trypsin digestion solution is added, and the cells are digested at 37°C for 3 minutes, and then the above culture medium is added to terminate the trypsin digestion; then centrifugation is performed at 300-400 rpm for 5 minutes, and the cells are harvested and resuspended in the above culture medium for passaging.
[0010] Preferably, the method for isolating the amniotic epithelial cells is to mechanically separate the amniotic layer and the chorionic layer of the placenta amniotic region from the freshly delivered placenta and amniotic tissue in a biological safety cabinet, and wash with PBS several times to remove blood and other contaminants;
[0011] Cut the amniotic membrane tissue of the placenta into 1 mm 3 For small pieces, wash the tissue again with PBS;
[0012] The amniotic tissue cut into small pieces is enzymatically digested to release the amniotic epithelial cells; the first digestion time is 10 minutes, and the digestion products are discarded; the second digestion time is 30 minutes, and the third digestion time is 30 minutes, and the second and third digestion products are combined, and then passed through a 70μm cell sieve and centrifuged at 300-400rpm for 5 minutes to collect the amniotic epithelial cells; the enzyme is a mixed solution of 250IU / ml type I collagenase, 300IU / ml trypsin, and 25000IU / ml DNase I enzyme.
[0013] Beneficial effects:
[0014] The culture medium of the invention can block cell senescence during the passage of amniotic epithelial cells, stably increase the passage number of amniotic epithelial cells to 10 generations, and significantly increase the passage number of the cells in the prior art.
[0015] As the culture generations increase, the number of cells obtained from the same batch increases significantly and can gradually meet clinical needs.
[0016] The culture medium and the culture method of the present invention are used to culture amniotic epithelial cells, which can not only reduce the production cost, but also improve the production stability and the operability of quality control. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0018] Figure 1 The cell status of hAECs of generations P1, P10, and P11 cultured in medium A. The scale bar is 100 μm.
[0019] Figure 2 The cell counting results of each generation of hAECs cells cultured in medium A; the horizontal axis is the number of cell passages, and the vertical axis is the cell counting results.
[0020] Figure 3 This is the flow cytometry result of hAECs cells cultured in medium A and P1 cells.
[0021] Figure 4 This is the flow cytometry result of hAECs cells cultured in medium A and P10 cells.
[0022] Figure 5 This is the flow cytometry result of hAECs cells cultured in medium A and P11 cells.
[0023] Figure 6 This is the cell status of P4 hAECs cultured in medium B.
[0024] Figure 7 These are the cell counting results of each generation of hAECs cells cultured in medium B.
[0025] Figure 8 The cell status of hAECs at P5 cultured in medium C.
[0026] Fig. 9 These are the cell counting results of each generation of hAECs cells cultured in medium C.
[0027] Fig.10 The cell status of hAECs at P6 cultured in medium D.
[0028] Fig.11 These are the cell counting results of each generation of hAECs cells cultured in medium D.
[0029] Fig.12 The cell status of hAECs at P5 cultured in medium E.
[0030] Fig.13 These are the cell counting results of each generation of hAECs cells cultured in medium E.
[0031] Fig.14 This is the cell status of hAECs at P8 cultured in medium F.
[0032] Fig.15 These are the cell counting results of each generation of hAECs cells cultured in medium F.
[0033] Fig.16 The cell status of hAECs at P7 cultured in medium G.
[0034] Fig.17 These are the cell counting results of each generation of hAECs cells cultured in medium G.
[0035] Fig.18 The cell status of hAECs at P8 cultured in medium H.
[0036] Fig.19 These are the cell counting results of each generation of hAECs cells cultured in medium H. DETAILED DESCRIPTION
[0037] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0038] The amniotic epithelial cells of the present invention are separated from postpartum placenta and amniotic tissue, and the placenta and amniotic tissue are donated voluntarily by pregnant women who have signed an informed consent form.
[0039] The reagents of the present invention are all commercially available, and their sources are not specifically limited, such as Rho kinase inhibitor (Hydroxyfasudil hydrochloride) (HY-13911A, MCE), p38MAPK inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) (HY-10256, MCE), protein kinase C inhibitor 3-[1-[3-(dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (Go 6983)(HY-13689, MCE), MEM non-essential amino acid solution (100×) (11140050, thermo), MEM amino acid solution (50×) (11130051, thermo), sodium pyruvate (S104174, Shanghai Aladdin Biochemical Technology Co., Ltd.), epidermal growth factor (EGF) (GMP-TL613, Beijing Tongli Haiyuan Biotechnology Co., Ltd.), β-mercaptoethanol (M301574, Shanghai Aladdin Biochemical Technology Co., Ltd.), basic fibroblast growth factor (GMP-TL401, Beijing Tongli Haiyuan Biotechnology Co., Ltd.), hydrocortisone (H657409, Shanghai Aladdin Biochemical Technology Co., Ltd.), insulin (I3536 sigma), UltraGRO (HPCPLCGL50, Helios), DMEM / F-12 (Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12) (21041025, thermo).
[0040] Example 1
[0041] 1. Pretreatment of placenta and amniotic tissue
[0042] The amniotic membrane is divided into the placental amniotic zone (including the central zone, intermediate zone, and peripheral zone near the umbilical cord), the reflected amniotic zone (connected to the extraembryonic fetal chorionic lobe), and the umbilical amniotic zone (covering the umbilical cord). Due to changes in mitochondrial activity and reactive oxygen species (ROS) levels, the morphological and functional properties of hAECs vary significantly between different placental regions. Significantly higher levels of potentially damaging ROS were found in the reflected amniotic zone, while higher mitochondrial activity was found in the placental amniotic zone. Along with higher mitochondrial activity, the proliferation capacity of hAECs isolated from the placental amniotic zone was found to be higher than that of the reflected amniotic zone.
[0043] Place the delivered placenta and amniotic tissue in a container filled with ice-cold PBS buffer and immediately transport it to the laboratory. In a biosafety cabinet, the amnion is stripped. The amniotic layer and the chorionic layer in the amniotic region of the placenta are mechanically separated. Wash several times with PBS to remove blood and other contaminants.
[0044] 2. Cut the amniotic membrane tissue in the placenta amniotic membrane area into 1mm 3 Washing the tissue again with PBS in small pieces to ensure complete removal of thrombi may improve the efficiency of trypsin during the digestion step.
[0045] 3. Tissue digestion: Enzymatic digestion of the amniotic tissue cut into small pieces to release epithelial cells. There are significant differences in the enzymatic digestion process of different schemes. We use a mixed solution of 250IU / ml type I collagenase, 300IU / ml trypsin, and 25000IU / ml DNase I enzyme to digest the tissue. The first digestion time is 10 minutes. Because the first digestion contains more impurities, the digestion product is discarded; the second digestion is 30 minutes, and the third digestion is 30 minutes. The second and third digestion products are combined. The number of primary hAECs cells obtained by digesting the tissue using a mixed solution of the enzymes of the present invention is higher than the digestion method using any two or three of the enzymes.
[0046] 4. Cell collection: After the combined second and third digestion products are passed through a 70 μm cell sieve, centrifuge at 300-400 rpm for 5 minutes, harvest the cells, and resuspend them in medium A. Perform cell counting and adjust the cell density to 4 x 10 5 cells / ml, inoculated into T175 cell culture flasks and recorded as P0 cells.
[0047] Culture medium A: DMEM / F-12 containing 10 μM Rho kinase inhibitor, 10 μM p38 MAPK inhibitor, 10 μM protein kinase C inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0048] 5. Cell culture: Culture the P0 cells in a 37°C, 5% carbon dioxide incubator. When the cell confluence is greater than 80%, add 5 ml of 300 IU / ml trypsin digestion solution, digest the cells at 37°C for 3 minutes, and then add 5 ml of culture medium A to stop the trypsin digestion.
[0049] Centrifuge at 300-400 rpm for 5 minutes, harvest the cells, and resuspend them in medium A. Perform a cell count and adjust the cell density to 4 x 10 5 cells / ml, and inoculated into multiple T175 cell culture flasks, recorded as P1 cells. At the same time, a corresponding number of cell samples were retained for flow cytometry detection.
[0050] 6. Subculture: Repeat the cell culture step in step 5 until the flow cytometry results show that one of the hAECs pluripotent stem cell markers decreases and the cell morphology begins to show spindle-shaped results.
[0051] Example 2
[0052] 1. The morphology of hAECs cultured according to the method of Example 1 was observed by photographing them with a Nikon inverted microscope (4×) (see Appendix Figure 1 ), as shown in the figure, the cells of the P1 and P10 generations are in a cobblestone shape; while at the P11 generation, they gradually appear in a long spindle shape, indicating that the hAECs cells of the 11th generation began to transform into hAMSCs cells.
[0053] 2. Count the hAECs cells cultured by the method in Example 1, repeat the counting three times, and calculate the mean ± standard deviation (see Appendix Figure 2 ), as shown in the figure, before P10, the cells basically showed a doubling trend. At P11, the cells no longer proliferated, but showed morphological changes.
[0054] 3. The purity and characteristics of hAECs cells were detected by flow cytometry (FCM), including cell surface antigens (PAN-FITC, SSEA4-PE, CD34-FITC, CD45-FITC, HLA-DR-PE, CD90-FITC, CD151-PE, CD326-PE) and nuclear antigens (OCT4-PE).
[0055] The hAECs cells were washed once with PBS (10010023, thermo) and then stained with TrypLE TMThe cells were digested with Express Enzyme (1X) (Gibco, 12605010). The cells were centrifuged at 500g for 5 minutes, and the cells were recovered. The cells were incubated with surface antigen fluorescent-labeled antibodies and their IgG controls at 4°C for 30 minutes, washed twice with PBS, and analyzed on CytoFLEX (Beckman), and the results were analyzed using CytExpert software (Beckman). When staining nuclear antigen, the cells were fixed with Foxp3 fixation / permeabilization working solution at room temperature in the dark for 60 minutes. After washing twice with 1X permeabilization working solution, the cells were incubated with nuclear antigen fluorescent-labeled antibodies and their IgG controls at 4°C for 1 hour, washed twice with 1X permeabilization working solution, and analyzed on CytoFLEX (Beckman), and the data were analyzed using CytExpert software.
[0056] The reagent information of this example is shown in Table 1, and the test results are shown in Table 2 and Appendix Figure 3-5 .
[0057] Table 1
[0058] Reagent name factory Part Number Dilution ratio PAN-FITC(MouseIgG1) Invitrogen MA5-28561 5μl / test SSEA4-PE(MouseIgG3) eBioscience 12-8843 5μl / test CD34-FITC(MouseIgG1) eBioscience 11-0349 5μl / test CD45-FITC(MouseIgG1) eBioscience 11-0459 5μl / test HLA-DR-PE(MouseIgG2a) eBioscience 12-9952 5μl / test CD90-FITC(MouseIgG1) Biolegend 328108 5μl / test CD151-PE(MouseIgG1) Biolegend 350408 5μl / test CD326-PE(MouseIgG1) eBioscience 12-9326 5μl / test OCT4-PE(RatIgG2a) eBioscience 12-5841 0.5μg / test MouseIgG1IsotypeControl-FITC eBioscience 11-4714 5μl / test MouseIgG1IsotypeControl-PE eBioscience 12-4714 5μl / test MouseIgG3IsotypeControl-PE eBioscience 12-4742 5μl / test MouseIgG2aIsotypeControl-PE eBioscience 12-4724 0.25μg / test RatIgG2aIsotypeControl-PE eBioscience 12-4321 0.5μg / test Foxp3 / Transcription Factor Flow Cytometry Immobilization Permeabilization Buffer eBioscience 00-5523-00 /
[0059] Table 2
[0060]
[0061] hAECs cells can express pluripotent stem cell markers (OCT-4, NANOG, SSEA-4), stem cell markers (CD90), epithelial cell markers (CD151, CD326), and almost no immunogenic markers (HLA-DR), hematopoietic stem cell markers (CD34), and leukocyte markers (CD45). From the results, it can be seen that compared with P1 and P10 cells, the expression of NANOG and CD326 in P11 cells dropped sharply, indicating that the pluripotency and epithelial properties of hAECs cells are disappearing; and the increase of CD90 indicates that hAECs cells are transforming into hAMSCs cells. Therefore, using medium A to culture hAECs cells can effectively prevent cell replication senescence and stably pass through 10 generations without losing the expression of pluripotent stem cell markers.
[0062] Example 3
[0063] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that the concentrations of the components in culture medium A were adjusted.
[0064] Culture medium A: DMEM / F-12 containing 5 μM Rho kinase inhibitor, 5 μM p38 MAPK inhibitor, 5 μM protein kinase C inhibitor, 1 mM L-glutamine, 0.5% MEM non-essential amino acid solution (100×), 0.5% MEM amino acid solution (50×), 0.5 mM sodium pyruvate, 10 ng / mL epidermal growth factor, 40 μM β-mercaptoethanol, 30 ng / mL basic fibroblast growth factor, 0.2 μg / ml hydrocortisone, 1 μg / ml insulin, and 1% UltraGRO.
[0065] Example 4
[0066] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that the concentrations of the components in culture medium A were adjusted.
[0067] Culture medium A: DMEM / F-12 containing 15 μM Rho kinase inhibitor, 15 μM p38 MAPK inhibitor, 15 μM protein kinase C inhibitor, 3 mM L-glutamine, 2% MEM non-essential amino acid solution (100×), 2% MEM amino acid solution (50×), 2 mM sodium pyruvate, 30 ng / mL epidermal growth factor, 70 μM β-mercaptoethanol, 70 ng / mL basic fibroblast growth factor, 0.6 μg / ml hydrocortisone, 10 μg / ml insulin, and 10% UltraGRO.
[0068] hAECs cells can express pluripotent stem cell markers (OCT-4, NANOG, SSEA-4), stem cell markers (CD90), epithelial cell markers (CD151, CD326), and almost no immunogenic markers (HLA-DR), hematopoietic stem cell markers (CD34), and leukocyte markers (CD45). The results of culturing hAECs cells with the medium A of Examples 3 and 4 are similar to those of Example 1, and can also be stably passaged for 10 generations. Compared with P1 and P10 cells, the expression of NANOG and CD326 in P11 generation cells decreases sharply, and CD90 increases.
[0069] Comparative Example 1
[0070] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that culture medium B was used to replace culture medium A.
[0071] Culture medium B: DMEM / F-12 containing 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0072] Comparative Example 2
[0073] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that culture medium C was used to replace culture medium A.
[0074] Culture medium C: DMEM / F-12 containing 10 μM Rho kinase inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0075] Comparative Example 3
[0076] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that culture medium D was used to replace culture medium A.
[0077] Culture medium D: DMEM / F-12 containing 10 μM p38 MAPK inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0078] Comparative Example 4
[0079] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that culture medium E was used to replace culture medium A.
[0080] Culture medium E: DMEM / F-12 containing 10 μM protein kinase C inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0081] Comparative Example 5
[0082] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that medium A was replaced by medium F.
[0083] Culture medium F: DMEM / F-12 containing 10 μM Rho kinase inhibitor, 10 μM p38 MAPK inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0084] Comparative Example 6
[0085] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that medium A was replaced by medium G.
[0086] Culture medium G: DMEM / F-12 containing 10 μM Rho kinase inhibitor, 10 μM protein kinase C inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0087] Comparative Example 7
[0088] The methods for isolating, collecting and culturing hAECs cells were the same as those in Example 1, except that medium A was replaced by medium H.
[0089] Culture medium H: DMEM / F-12 containing 10 μM p38 MAPK inhibitor, 10 μM protein kinase C inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
[0090] Comparative Example 8
[0091] The cell morphology, cell number and expression of pluripotent stem cell markers of the hAECs subcultured in Comparative Examples 1-7 were detected using the same detection method as in Example 2.
[0092] 1. After testing, hAECs cells cultured in medium B were cobblestone-like at P3 and before, and basically showed a doubling trend; at P4, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Figure 6 , 7 and Table 3).
[0093] Table 3
[0094]
[0095] 2. The hAECs cells cultured in medium C were found to be cobblestone-like at P4 and before, and basically showed a doubling trend; at P5, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Figure 8 , 9 and Table 4).
[0096] Table 4
[0097]
[0098] 3. After testing, hAECs cells cultured in medium D were cobblestone-like at P5 and before, and basically showed a doubling trend; at P6, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Fig.10 , 11 and Table 5).
[0099] Table 5
[0100]
[0101]
[0102] 4. After testing, hAECs cells cultured in medium E were cobblestone-like at P4 and before, and basically showed a doubling trend; at P5, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Fig.12 , 13 and Table 6).
[0103] Table 6
[0104]
[0105] 5. The hAECs cells cultured in medium F were tested to be cobblestone-like at P7 and before, and basically showed a doubling trend; at P8, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Fig.14 , 15 and Table 7).
[0106] Table 7
[0107]
[0108] 6. After testing, hAECs cells cultured in medium G were cobblestone-like at P6 and before, and basically showed a doubling trend; at P7, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Fig.16 , 17 and Table 8).
[0109] Table 8
[0110]
[0111]
[0112] 7. The hAECs cells cultured in medium H were tested to be cobblestone-like at P7 and before, and basically showed a doubling trend; at P8, the cells gradually became spindle-shaped and no longer proliferated (see Appendix Fig.18 , 19 and Table 9).
[0113] Table 9
[0114]
[0115] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0116] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. An amniotic epithelial cell culture medium, characterized in that The culture medium comprises: DMEM / F-12 containing 5-15 μM of Rho kinase inhibitor, 5-15 μM of p38 MAPK inhibitor, 5-15 μM of protein kinase C inhibitor, 1-3 mM of L-glutamine, 0.5-2% of MEM non-essential amino acid solution (100×), 0.5-2% of MEM amino acid solution (50×), 0.5-2 mM of sodium pyruvate, 10-30 ng / mL of epidermal growth factor, 40-70 μM of β-mercaptoethanol, 30-70 ng / mL of basic fibroblast growth factor, 0.2-0.6 μg / ml of hydrocortisone, 1-10 μg / ml of insulin, and 1-10% of UltraGRO.
2. The amniotic epithelial cell culture medium according to claim 1, characterized in that The culture medium comprises: DMEM / F-12 containing 10 μM Rho kinase inhibitor, 10 μM p38 MAPK inhibitor, 10 μM protein kinase C inhibitor, 2 mM L-glutamine, 1% MEM non-essential amino acid solution (100×), 1% MEM amino acid solution (50×), 1 mM sodium pyruvate, 20 ng / mL epidermal growth factor EGF, 55 μM β-mercaptoethanol, 50 ng / mL basic fibroblast growth factor, 0.4 μg / ml hydrocortisone, 5 μg / ml insulin, and 5% UltraGRO.
3. A method for culturing amniotic epithelial cells, characterized in that: The amniotic epithelial cells are cultured using the culture medium of claim 2 at a temperature of 37° C. and 5% CO 2 .
4. The method for culturing amniotic epithelial cells according to claim 3, characterized in that: When the cell confluence is greater than 80%, add 300 IU / ml trypsin digestion solution, digest the cells at 37°C for 3 minutes, then add the culture medium described in claim 1 to stop the trypsin digestion; then centrifuge at a speed of 300-400 rpm for 5 minutes, harvest the cells and resuspend them in the culture medium described in claim 1 for passaging.
5. The method for culturing amniotic epithelial cells according to claim 3, characterized in that: The method for separating the amniotic epithelial cells is to mechanically separate the amniotic layer and the chorionic layer of the placenta amniotic region of the placenta from the amniotic tissue just delivered in a biological safety cabinet, and wash with PBS 2 to 3 times to remove blood and other contaminants; Cut the amniotic membrane tissue of the placenta into 1 mm 3 For small pieces, wash the tissue again with PBS; The amniotic tissue cut into small pieces was enzymatically digested to release the amniotic epithelial cells; the first digestion time was 10 minutes, and the digestion product was discarded; The second digestion was performed for 30 minutes, and the third digestion was performed for 30 minutes. The second and third digestion products were combined, and then passed through a 70 μm cell sieve and centrifuged at 300-400 rpm for 5 minutes to collect the amniotic epithelial cells; the enzyme was a mixed solution of 250 IU / ml type I collagenase, 300 IU / ml trypsin, and 25000 IU / ml DNase I enzyme.
